Regeneron’s first quarter 2025 results miss expectations

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the first quarter of 2025, showing that total revenues declined 4% to $3.03 billion.

On a non-generally accepted accounting principles (GAAP) basis, net income came in at $928 million, down 17% compared with the same period last year, with non-GAAP diluted net income per share of $8.22, down 14%.

Analysts called for a more bullish income per share of $8.62 and sales of $3.25 billion, respectively, leading to Regeneron’s shares tumbling.9.5% to $552.89.